BackgroundWhile sublingual immunotherapy (SLIT) is effective for allergic rhinitis (AR), most studies focus on subjective symptom relief, with limited data on objective signs and biomarkers. This study evaluates the effects of 3-year house dust mite (HDM) SLIT on nasal mucosal signs and peripheral blood eosinophil (EOS) counts in AR patients.MethodsThis study retrospectively analyzed the data of 86 AR patients (aged 14–57) who had received 3 years of SLIT treatment.
Subjective scores including the total nasal symptom score (TNSS), total medication score (TMS), combined symptom and medication score (CSMS), and visual analog scale (VAS) were assessed at baseline, 1.5 years, and 3 years. Objective assessment of nasal mucosal pathology was performed via nasal endoscopy and quantified using the modified Lund-Kennedy (MLK) scoring system.
Additionally, EOS counts and the level of serum total IgE were also measured.ResultsAt 1.5 and 3 years, significant reductions were observed in TNSS, TMS, CSMS, VAS, and MLK scores compared to baseline and between these timepoints (all p < 0.001). Nasal endoscopy at the 3-year follow-up revealed marked improvement in nasal mucosal edema and secretions.
Frontiers in Immunology published a clinical update in Infectious Disease on 28 Apr 2026.
The item focuses on Improvement in nasal signs and eosinophils following 3 years of sublingual immunotherapy for allergic rhinitis.
Review the original article for the full source wording and details.